Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients
Sponsor: Poxel SA
Listed as NCT04321343, this PHASE2 trial focuses on NASH - Nonalcoholic Steatohepatitis and remains completed. Sponsored by Poxel SA, it has been updated 9 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Sep 2023 [monthly]
Completed PHASE2
-
Sep 2022 — Apr 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jan 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Poxel SA
For direct contact, visit the study record on ClinicalTrials.gov .